The Gilead SARS-CoV-2 drug, GS-621763, is an oral prodrug of the parent nucleoside of remdesivir (GS-441524) which demonstrated therapeutic and prophylactic efficacy in a ferret model of SARS-CoV-2 infection, significantly reducing viral load to near-undetectable levels with twice-daily administration. Remdesivir is already FDA [...]
< 1 minute read
Dec. 20, 2021
GS-621763: an Oral Prodrug for SARS-CoV-2
GS-621763
oral antiviral prodrug of remdesivir effective in a ferret SARS-CoV-2 model from remdesivir nucleoside (GS-441524) Nature Communications Gilead Sciences Inc.
Loading...
